Sylvamo Corporation (SLVM)

SELLAS Life Sciences Group Inc. surged as promising clinical news boosted investor optimism; stocks have been trading up by 14.72 percent. Key Takeaways For SLS Traders Q1 loss came in at $0.05 per share, beating the $0.06 Street view and improving from a $0.07 loss last year.

Sylvamo (SLVM) delivered earnings and revenue surprises of -116.33% and +5.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

SELLAS Life Sciences Group Inc. jumped as stocks have been trading up by 13.7 percent on promising clinical trial progress Key Takeaways Q1 loss of $0.05 per share at SELLAS Life Sciences came in better than the $0.06 loss Wall Street expected. The Q1 loss also narrowed from $0.07 per share ...

Sylvamo (SLVM) shares have been reacting to a weak first quarter, in which the company moved from a profit to a small loss. Management also highlighted ongoing operational issues in Europe and Brazil. See our latest analysis for Sylvamo. The weak first quarter and guidance on ongoing operational ...

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Sylvamo (SLVM) Q1 2026 Earnings Transcript was originally published by The Motley Fool